经导管动脉内化疗栓塞联合经皮射频消融术治疗中晚期肝癌的预后  

Prognostic of transcatheter arterial chemoembolization combined with percutaneous radiofrequency ablation in the treatment of middle and advanced liver cancer

作　　者：王颖 WANG Ying(Radiology Department, Xi＇an Fengcheng Hospital, Xi＇an 710009, China)

机构地区：[1]西安凤城医院放射科,陕西西安710009

出　　处：《临床医学研究与实践》2018年第19期50-51,共2页Clinical Research and Practice

摘　　要：目的探讨经导管动脉内化疗栓塞(TACE)联合经皮射频消融术(RFA)治疗中晚期肝癌的预后效果。方法选择63例在我院接受治疗的中晚期肝癌患者,根据患者意愿分为试验组(30例)和对照组(33例)。试验组采用TACE+经皮RFA治疗,对照组采用TACE治疗。比较两组的疗效及毒副作用发生情况。结果试验组的治疗总有效率显著高于对照组(P<0.05)。试验组的1、2、3年生存率及平均生存期均优于对照组(P<0.05)。两组的毒副作用发生率无显著差异(P>0.05)。结论 TACE联合经皮RFA治疗中晚期肝癌的疗效显著,能够明显延长患者的生存期,改善预后。Objective To evaluate the prognostic effect of transcatheter arterial chemoembolization（TACE） combined with percutaneous radiofrequency ablation（RFA） in the treatment of middle and advanced liver cancer. Methods A total of 63 patients with middle and advanced liver cancer treated in our hospital were selected and divided into experimental group（n=30） and control group（n=33） according to their wishes. The experimental group was treated with TACE＋percutaneous RFA,while the control group was treated with TACE. The effects, occurrence of toxic and side effects in the two groups were compared. Results The total effective rate of treatment in the experimental group was significantly higher than that of the control group（P〈0.05）. The survival rate of 1, 2, 3 years and average lifetime in the experimental group were better than those in the control group（P〈0.05）. There was no significant difference in incidences of toxic and side effects between the two groups（P〉0.05）. Conclusion TACE combined with percutaneous RFA is effective in the treatment of middle and advanced liver cancer. It can obviously prolong the life period and improve the prognostic of the patients.

关 键 词：经导管动脉内化疗栓塞(TACE) 经皮射频消融术(RFA) 中晚期肝癌 

分 类 号：R735.7[医药卫生—肿瘤]